Testing for Homologous Recombination Deficiency in Ovarian & Other Tumor Types
Time: 3:15 pm
day: Day One Track B PM
Details:
- Myriad developed the MyChoice CDx test to identify patients with homologous recombination deficient (HRD) tumors
- Many other HRD tests show limited agreement with the clinically validated companion diagnostic test
- MyChoice CDx is approved for ovarian cancer, but may have applications in breast and prostate cancer